<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>A total of 46 patients with <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> (34 severe; 12 moderate) were treated with antihuman thymocyte globulin (ATG), high-dose <z:chebi fb="0" ids="6888">methylprednisolone</z:chebi>, and oxymetholone </plain></SENT>
<SENT sid="1" pm="."><plain>Early symptoms of ATG toxicity included <z:hpo ids='HP_0001945'>fever</z:hpo>, <z:e sem="disease" ids="C0015230" disease_type="Disease or Syndrome" abbrv="">rash</z:e>, and <z:e sem="disease" ids="C0006266" disease_type="Disease or Syndrome" abbrv="">bronchospasm</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>Signs of <z:e sem="disease" ids="C0036830" disease_type="Disease or Syndrome" abbrv="">serum sickness</z:e> also developed in 23 patients </plain></SENT>
<SENT sid="3" pm="."><plain>Complications associated with high doses of steroids were <z:hpo ids='HP_0003074'>hyperglycemia</z:hpo>, <z:hpo ids='HP_0000822'>hypertension</z:hpo>, fluid retention, <z:hpo ids='HP_0002239'>gastrointestinal hemorrhage</z:hpo>, and <z:hpo ids='HP_0010885'>aseptic necrosis</z:hpo> of the hip </plain></SENT>
<SENT sid="4" pm="."><plain>Other morbidity possible associated with steroid administration included <z:hpo ids='HP_0001250'>seizures</z:hpo>, <z:hpo ids='HP_0011675'>arrhythmias</z:hpo>, and <z:hpo ids='HP_0002315'>headache</z:hpo> with <z:hpo ids='HP_0001085'>papilledema</z:hpo> </plain></SENT>
<SENT sid="5" pm="."><plain>Studies of elevated liver function necessitated discontinuation of <z:chebi fb="3" ids="50113">androgen</z:chebi> therapy in eight patients </plain></SENT>
<SENT sid="6" pm="."><plain>A complete or partial hematological response was noted in 19 patients (41%) </plain></SENT>
<SENT sid="7" pm="."><plain>Of these, three have had recurrent cytopenias, of whom one has developed a <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> </plain></SENT>
<SENT sid="8" pm="."><plain>There are currently 34 patients surviving, and 12 who have died </plain></SENT>
<SENT sid="9" pm="."><plain>Actuarial survival at three years is 65% </plain></SENT>
<SENT sid="10" pm="."><plain>These response and survival data are comparable to those of previous trials using ATG and <z:chebi fb="5" ids="50113">androgens</z:chebi> without high-dose steroids </plain></SENT>
<SENT sid="11" pm="."><plain>A prospective, randomized trial is needed to determine whether the addition of high-dose <z:chebi fb="0" ids="50858">corticosteroids</z:chebi> to ATG does significantly increase the rate and frequency of response in order to justify the toxicity of this additional immunosuppressive therapy in the treatment of <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> </plain></SENT>
</text></document>